Adequacy of pharmacotherapy among medicaid-enrolled patients newly diagnosed with obsessive-compulsive disorder

CNS Spectrums

Volumn 14, Issue 12, 2009, Pages 695-703

  Hankin, Cheryl S ^a   Koran, Lorrin M ^b   Bronstone, Amy ^c   Black, Donald W ^d   Sheehan, David V ^e   Hollander, Eric ^f   Dunn, Jeffrey D ^g   Culpepper, Larry ^h   Knispel, John ⁱ   Dougherty, Darin D ^j,k   Wang, Zhaohui ^c  

^a BioMedEcon LLC   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BioMedEcon   (United States)

^d UNIVERSITY OF IOWA   (United States)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^g SelectHealth Inc   (United States)

^h BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ Knispel Associates   (United States)

^j HARVARD MEDICAL SCHOOL   (United States)

^k MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANXIOLYTIC AGENT; CENTRAL STIMULANT AGENT; CITALOPRAM; CLOMIPRAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HYPNOTIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; PAROXETINE; SEDATIVE AGENT; SERTRALINE; VENLAFAXINE;

ADULT; ARTICLE; COGNITIVE THERAPY; COST OF ILLNESS; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; OBSESSIVE COMPULSIVE DISORDER; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 77749291834     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900023956     Document Type: Article

References (37)

1. Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry. 2007;164(7 Suppl):5-53.
2. Committee to Advise the Public Health Service on Clinical Practice Guidelines, Institute of Medicine. Clinical Practice Guidelines: Directions of a New Program. Washington, DC: National Academy Press; 1990.
3. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593-602.
4. Koran LM. Quality of life in obsessive-compulsive disorder. Psychiatr Clin North Am. 2000;23:509-517.
5. Mendlowicz MV, Stein MB. Quality of life in individuals with anxiety disorders. Am J Psychiatry. 2000;157:669-682.
6. Van Ameringen M, Mancini C, Farvolden P. The impact of anxiety disorders on educational achievement. J Anxiety Disord. 2003;17:561-571.
7. Katzelnick DJ, Kobak KA, DeLeire T, et al. Impact of generalized social anxiety disorder in managed care. Am J Psychiatry. 2001;158:1999-2007.
8. Roy-Byrne P, Russo J, Dugdale DC, Lessler D, Cowley D, Katon W. Undertreatment of panic disorder in primary care: role of patient and physician characteristics. J Am Board Fam Pract. 2002;15:443-450.
9. Stein MB, Sherbourne CD, Craske MG, et al. Quality of care for primary care patients with anxiety disorders. Am J Psychiatry. 2004;161:2230-2237.
10. Young AS, Klap R, Sherbourne CD, Wells KB. The quality of care for depressive and anxiety disorders in the United States. Arch Gen Psychiatry. 2001;58:55-61.
11. Blanco C, Olfson M, Stein DJ, Simpson HB, Gameroff MJ, Narrow WH. Treatment of obsessive-compulsive disorder by US psychiatrists. J Clin Psychiatry. 2006;67:946-951.
12. Denys D, van Megen H, Westenberg H. The adequacy of pharmacotherapy in outpatients with obsessive-compulsive disorder. Int J Psychopharmacol. 2002;17:109-114.
13. Eisen JL, Goodman WK, Keller MB, et al. Patterns of remission and relapse in obsessive-compulsive disorder: a 2-year prospective study. J Clin Psychiatry. 1999;60:346-351; quiz 352.
14. Koran LM, Leventhal JL, Fireman B, Jacobson A. Pharmacotherapy of obsessive-compulsive disorder in a health maintenance organization. Am J Health Syst Pharm. 2000;57:1972-1978.
15. Karno M, Golding JM, Sorenson SB, Burnam MA. The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry. 1988;45:1094-1099.
16. Davidson JR, Hughes DL, George LK, Blazer DG. The epidemiology of social phobia: findings from the Duke Epidemiological Catchment Area Study. Psychol Med. 1993;23:709-718.
17. Mancebo MC, Greenberg B, Grant JE, et al. Correlates of occupational disability in a clinical sample of obsessive-compulsive disorder. Compr Psychiatry. 2008;49:43-50.
18. DuPont RL, Rice DP, Shiraki S, Rowland CR. Economic costs of obsessive-compulsive disorder. Med Interface. 1995;8:102-109.
19. Weisberg RB, Dyck I, Culpepper L, Keller MB. Psychiatric treatment in primary care patients with anxiety disorders: a comparison of care received from primary care providers and psychiatrists. Am J Psychiatry. 2007;164:276-282.
20. Russell AJ, Mataix-Cols D, Anson M, Murphy DG. Obsessions and compulsions in Asperger syndrome and high-functioning autism. Br J Psychiatry. 2005;186:525-528.
21. Fireman B, Koran LM, Leventhal JL, Jacobson A. The prevalence of clinically recognized obsessive-compulsive disorder in a large health maintenance organization. Am J Psychiatry. 2001;158:1904-1910.
22. Hollander E, Stein DJ, Kwon JH, et al. Psychosocial function and economic costs of obsessive-compulsive disorder. CNS Spectr. 1997;2:16-25.
23. Pinto A, Mancebo MC, Eisen JL, Pagano ME, Rasmussen SA. The Brown Longitudinal Obsessive Compulsive Study: clinical features and symptoms of the sample at intake. J Clin Psychiatry. 2006;67:703-711.
24. Marangell LB, Silver JM, Goff DC, Yudofsky SC. Psychopharmacology and Electroconvulsive Therapy. In: Hales RE, Yudofsky SC, eds. The American Psychiatric Publishing Textbook of Clinical Psychiatry, Fourth Edition. Washington, DC: American Psychiatric Publishing; 2003:1047-1150.
25. Olfson M, Marcus SC, Tedeschi M, Wan GJ. Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry. 2006;163:101-108.
26. Bull SA, Hunkeler EM, Lee JY, et al. Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother. 2002;36:578-584.
27. McGettigan P, Kelly A, Carvahlo M, Feely J. Anti-depressants in primary care: analysis of treatment discontinuations. Pharmacoepidemiol Drug Saf. 2000;9:521-528.
28. Stein DJ, Andersen EW, Tonnoir B, Fineberg N. Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Curr Med Res Opin. 2007;23:701-711.
29. Miller BJ. A review of second-generation antipsychotic discontinuation in first-episode psychosis. J Psychiatr Pract. 2008;14:289-300.
30. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;356:1711-1722.
31. LaSalle VH, Cromer KR, Nelson KN, Kazuba D, Justement L, Murphy DL. Diagnostic interview assessed neuropsychiatric disorder comorbidity in 334 individuals with obsessive-compulsive disorder. Depress Anxiety. 2004;19:163-173.
32. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999;282:1458-1465.
33. Hayward RS. Clinical practice guidelines on trial. CMAJ. 1997;156:1725-1727.
34. Lomas J, Anderson GM, Domnick-Pierre K, Vayda E, Enkin MW, Hannah WJ. Do practice guidelines guide practice? The effect of a consensus statement on the practice of physicians. N Engl J Med. 1989;321:1306-1311.
35. Woolf SH. Practice guidelines: a new reality in medicine. III. Impact on patient care. Arch Intern Med. 1993;153:2646-2655.
36. Trivedi MH, Lin EH, Katon WJ. Consensus recommendations for improving adherence, self-management, and outcomes in patients with depression. CNS Spectr. 2007;12(8 Suppl 13):1-27.
37. Bull SA, Hu XH, Hunkeler EM, et al. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA. 2002;288:1403-1409.